NEW YORK (GenomeWeb) – Molecular diagnostics developer DiaCarta announced today that its DiaCarta Clinical Services Laboratory has successfully passed the State of California survey under the Clinical Laboratory Improvement Amendments of 1988.

The lab now has permission to begin offering patient and clinical testing services for its QClamp-based molecular diagnostic. QClamp screens for tumor oncogenic driver and resistance mutations in tumor DNA derived from cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.